Sagimet Biosciences (SGMT) Operating Income (2022 - 2026)

Sagimet Biosciences' Operating Income history runs 5 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• In Q1 2026, Operating Income rose 41.04% year-over-year to -$11.7 million; the TTM figure through Mar 2026 stood at -$48.7 million (up 25.65% YoY), while the FY2025 annual figure was -$56.9 million, down 4.47% from the prior year.
• Operating Income was -$11.7 million for Q1 2026 at Sagimet Biosciences, down from -$10.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$6.8 million in Q1 2023 to a low of -$19.9 million in Q1 2025.
• Historically, Operating Income has averaged -$11.0 million across 5 years, with a median of -$10.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Operating Income tumbled 126.81% in 2024, then jumped 41.04% in 2026.
• A 5-year view of Operating Income shows it stood at -$7.4 million in 2022, then fell by 28.13% to -$9.5 million in 2023, then slumped by 92.21% to -$18.2 million in 2024, then jumped by 40.84% to -$10.8 million in 2025, then retreated by 8.81% to -$11.7 million in 2026.
• The last three Operating Income figures came in at -$11.7 million (Q1 2026), -$10.8 million (Q4 2025), and -$14.3 million (Q3 2025), per Business Quant data.